The PhD Programme in Molecular and Experimental Medicine (MEM) aims to address some of the main challenges of life sciences in a highly competitive scientific research environment
The MEM PhD Programme provides training in various fields of life sciences and molecular medicine offering a stimulating environment with access to state-of-the-art technology and clinical case lists for translational studies.
Two different curricula are available, candidates are required to specify their curriculum preferences when applying.
- The MEM Curriculum provides for the research activities to develop along, yet not remain limited to, the following main areas, including: oncological immunopathology, molecular cardiometabolics, genetics, neurosciences. An overall vision of regenerative and precision medicine is the theme running throughout the programme. The curriculum provides specific training for enabling technologies, such as imaging, flow cytometry, genomics and bioinformatics.
- The MEM-Clinical Curriculum aims to combine basic or clinical experimental research activities with clinical practice involving patient enrolment and assessment in specific trials. The course provides for ordinary clinical practice in the hospital under the supervision of a doctor (up to a maximum of 20 hours per week) and experimental laboratory activities, which include but are not limited to cellular and molecular biology, information technology, immunology and the use of preclinical models. Candidates will be directly responsible for research projects approved by their clinical supervisor and/or laboratory head.
For both curricula, the PhD will be conducted in a stimulating environment involving the organisation of Journal clubs and seminars given by national and international speakers, participation in congresses, informal meetings between different disciplines, encouraging researchers to work independently and collaboration with groups abroad. Liaising with tutors and non-Italian discussants further develops the international dimension.
Career Opportunities for Humanitas PhD students
The PhD program aims to train experts in clinical and industrial research, preparing them to take up careers in biotech companies, translational research, in clinical or academic fields worldwide. Thanks to a “translational” approach, professionals will quickly transfer new knowledge from basic sciences to bio-medicine with the aim of creating new and advanced diagnostic and therapeutic applications.
|PhD Coordinator: Prof Maria Rescigno|
The number of available places and/or scholarships may increase in the event that external funding becomes available by the deadline set for the completion of the call application procedure.
|Beginning of the academic year
1st November 2021
|Call for applications 2021 (EN)|
|First Ranking List
The shortlisted candidates will receive an email with detailed instructions on the interview process, that will take place on 13th, 14th and 16th September 2021.
The PhD course in Molecular and Experimental is articulated into three main types of didactic activities:
Every student is assigned a research topic under the supervision of a Supervisor; the research activity in the laboratory is a full-time activity
Mandatory frontal activities
Linguistics, Informatics, Research management and funding, Intellectual property are the main topics
- Mandatory courses
|Scientific Methods||I||Rosella Visintin||1,5|
|Scientific Writing||II||Miriam Alcalay||1,5|
- Seminar series (Journal Club on a specific topic between the speaker and the PhD students followed by a public seminar on the same topic)
Seminars and courses, offered by the Humanitas University and Humanitas Research Labs, which the PhD students can freely join according to their research field and interests.
Applicants wishing to enrol on the PhD course in Molecular and Experimental Medicine, MEM Curriculum must either have a “laurea magistrale” awarded in accordance with D.M. 270/2004 or equivalent qualification awarded by a foreign university (usually referred to as a Master’s Degree), in one of the subjects listed in the official call for applicants.
Applicants who are waiting to be awarded the required qualification at the date of submission can also take part in the selection process providing they have passed all of the Degree course exams at the time of the online application and are awarded the qualification before the beginning of the academic activities. In the event these applicants pass the selection process, their enrolment on the PhD course is conditional upon providing proof that the qualification is awarded.
Applicants wishing to enrol on the PhD Course in Molecular and Experimental Medicine, MEM-Clinical Curriculum must:
- be enrolled on the Medical Register
- already possess a specialist medical qualification
Alternatively, applications will also be taken from doctors in specialist training who will enrol in the final year in a School of Specialisation at Humanitas University
Doctors in specialist training who are already enrolled in the final year of Specialisation at any university and who will complete their training by 31st October 2021. In the event these applicants pass the selection process, they may conditionally enrol on the PhD Course and are required to provide proof of the awarded qualification by the beginning of academic activities.
Fees and Scholarships
PhD students are required to pay an annual fee for access and attendance, set at €250,00 for the academic year 2021/2022, including the regional tax and stamp duty.
Detailed information about each topic’s scholarship or equivalent contract can be found in the research topics table below, by clicking on each topic ID.
How to Apply
- Registration or access with your LOGINMIUR credentials
- Application form submission
- Payment of the application contribution
The application form must be completed in all its parts, on penalty of exclusion. In particular, applicants must submit all of the following documents in PDF format:
- Curriculum vitae
- Motivation letter
- Copy of a valid ID or passport (for Non-EU citizens)
- Diploma Supplement
- Copy of the receipt of payment of € 30,00
Additionally, applicants may indicate name and contacts of maximum two referees, preferably chosen among those who have had a supervising role of the candidates. The referees will be directly contacted by Humanitas University and asked to complete a brief letter of reference.
Further details about the application procedure will be reported in the official call for applicants.
Admission to the PhD Programme is based on a public selection process consisting of:
- the comparative evaluation of the titles and qualifications and
- an interview carried out in English by a Committee composed of a maximum of seven members.
The aim of the selection process is to assess the knowledge, competencies and aptitude of the applicants for scientific research as well as their motivation for undertaking the PhD programme.
Prior to the interview, applicants may be asked to take a multiple choice test, aimed at assessing the applicant’s specific knowledge in the fields of the research projects of the Campus.
A good knowledge of English is required and will be tested during the interview.
Should reasons justify it, the test and interview can be conducted via video-conference. Those who intend to conduct the interview via video-conference or request special assistance should specify this on the application form.
|Topic ID||Project Title||Curriculum||Pre-clinical Supervisor||Clinical Supervisor||Laboratory Name||Clinical Unit Name|
|MEM 1||DRG mutations in prostate cancer: a guiding light for enhanced screening and personalised therapy||Clinical||Stefano Duga||Massimo Lazzeri||Medical genetic and RNA biology Lab||Department of Urology|
|MEM 2||Investigating UBE3A-dependent sumoylation imbalance in the pathogenesis of the Angelman syndrome and autism||Standard||Michela Matteoli
|–||Pharmacology and Brain Pathology Lab||–|
|MEM 3||IPSCs from Duchenne Muscular Dystrophy: perfect genetic correction by chromosome transplantation and generation of 3D cell culture||Standard||Marianna Paulis
|–||Humanitas-Stem cell Lab||–|
|MEM 4||Tracing the brain circuits underlying traumatic memory attenuation||Standard||Michela Matteoli
Bianca A. Silva
|–||Circuits Neuroscience Lab||–|
|MEM 5||Investigating the role of the innate immune molecule, PTX3, in neurodevelopmental diseases||Standard||Elisabetta Menna
|–||Pharmacology and Brain Pathology Lab||–|
|MEM 6||Materials and tools for improving pancreatic surgery||Clinical||Maria Laura Costantino||Alessandro Zerbi
|Physico-chemical characterisation of pancreatic tissue Lab||Pancreatic Surgery|
|MEM 7||Immunological mechanisms of tumor immunotherapy-induced cardiotoxicity||Standard||Marinos Kallikourdis||–||Adaptive Immunity Lab||–|
|MEM 9||Clinical implementation of Artificial Intelligence algorithms to automate the Total Marrow Lymph-nodes Irradiation||Clinical||Carmelo Carlo-Stella
|Arturo Chiti||Advanced Imaging Lab||Radiotherapy and Radiosurgery Unit|
|MEM 10||To evaluate the role of innate immunity in tumor immunoediting and in response to cancer immunotherapies||Standard||Jaillon Sebastien||–||Experimental immunopathology Lab||–|
|MEM 11||Cancer-neuronal crosstalk in glioblastoma: novel therapeutic opportunities||Standard||Michela Matteoli||–||Pharmacology and Brain Pathology Lab||–|
|MEM 12||Role of the microbiota in tumor metastasis formation||Standard||Maria Rescigno||–||Mucosal immunology and microbiota Unit||–|
|MEM 13||Role of the microbiota in the gut-liver-brain axis||Standard||Maria Rescigno||Mucosal immunology and microbiota Unit||–|
|MEM 14||Dissecting the role of HCN1 in Developmental and Epileptic Encephalopathy (DEE) by exploiting patient-specific models of cerebral cortex development in vivo and in 3D cortical organoids||Standard||Simona Lodato
|–||Developmental Neurobiology Lab||–|
|MEM 15||Definition of cellular identity modification in the human myocardium during disease||Standard||Gianluigi Condorelli||Gianluigi Condorelli||Molecular Cardiology Lab||Department of Cardiovascular Medicine|
|MEM 16||PANTHER: Personalized medicine for primary cardiomyopathies: assessment of prognostic, diagnostic and therapeutic value of iPSC-based models in a large cohort of patients with dilated cardiomyopathy||Standard||Elisa Di Pasquale
|–||Department of Cardiovascular Medicine – Stem Cells Lab||–|
|MEM 17||ARTInGLIO: evaluation of Adaptive Radiation Therapy In GLIOblastoma||Clinical||Michela Matteoli
Luigi Maria Terracciano
|Pharmacology and Brain Pathology Lab||Radiotherapy and Radiosurgery Department|
|MEM 18||Role and predictive potential of distinct circulating and tumor-associated neutrophil subsets in progression and therapeutic response of malignant gliomas||Standard||Raffaella Bonecchi||–||Chemokine biology Lab||–|
|MEM 20||Cellular immune responses against human cancer||Standard||Enrico Lugli||–||Translational Immunology Lab||–|
|MEM 21||Utilization and validation of disruptive liquid biopsy methodology in Ulcerative Colitis||Standard||Stefania Vetrano||–||Gastrointestinal Immunopathology Lab||–|